SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Proteomic alterations in cerebrospinal fluid of spinal muscular atrophy patients undergoing nusinersen therapy: a systematic review and meta-analysis of potential biomarkers of treatment response.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis synthesizes evidence on cerebrospinal fluid (CSF) proteomic alterations in patients with spinal muscular atrophy (SMA) treated with nusinersen. Across 21 studies, consistent post-treatment decreases were observed in neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNF-H), and tau protein, which correlated with motor improvement, particularly in younger patients. Synaptic stress markers (e.g., α-synuclein, DJ-1) and metabolic proteins (e.g., apolipoprotein A1, transthyretin) demonstrated dynamic responses, suggesting systemic effects of therapy, while inflammatory cytokines and glial markers showed inconsistent trends. Extracellular matrix proteins and muscle-specific microRNAs emerged as promising indicators of musculoskeletal remodeling and treatment response. To evaluate clinical outcomes, a meta-analysis of 12 studies (n = 195 pre-treatment; n = 175 post-treatment) revealed a statistically significant mean improvement of 3.33 points in Hammersmith Functional Motor Scale Expanded (HFMSE) scores following nusinersen therapy (95% CI: –6.22 to –0.43; p = 0.02), with no heterogeneity (I² = 0%), indicating consistent functional gains across SMA populations. Overall, these findings suggest that HFMSE is a responsive clinical outcome measure in nusinersen-treated patients with SMA and that CSF proteomic profiling may provide complementary insights into biological treatment effects. However, given the heterogeneity in study design, patient characteristics, and proteomic platforms, the current evidence should be interpreted cautiously. Further large-scale, standardized, and longitudinal studies are required to validate candidate biomarkers and to clarify their integration with motor function assessments in monitoring treatment response in SMA.
Indexed as
Identifiers
42026258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.